ST广物：2025年前三季度净利润约3.18亿元

Group 1 - ST Guangwu reported a revenue of approximately 2.051 billion yuan for the first three quarters of 2025, a year-on-year decrease of 20.09% [1] - The net profit attributable to shareholders was about 318 million yuan, down 24.55% year-on-year [1] - Basic earnings per share were 0.27 yuan, reflecting a decrease of 22.86% compared to the previous year [1] Group 2 - As of the report date, ST Guangwu's market capitalization stood at 10.5 billion yuan [2] - The Chinese innovative drug sector has seen overseas licensing sales reach 80 billion USD this year [2] - There is a contrast in the biopharmaceutical secondary market's activity compared to the primary market, which is experiencing a fundraising slowdown [2]